NCT07148310 Hepatocellular Carcinoma Identification Using Delta-HLD
| NCT ID | NCT07148310 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Epiliquid Holding, Inc |
| Condition | Hepato Cellular Carcinoma (HCC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-05-18 |
| Primary Completion | 2026-08-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2023-05-18 with a primary completion date of 2026-08-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed HCC (cases) or clinically confirmed liver cirrhosis without HCC (controls) * Willing and able to provide informed consent * Available paired plasma and liver tissue sample Exclusion Criteria: * Other active cancers * Prior liver transplantation * Known hereditary cancer syndromes * Recent chemotherapy or antiviral treatment (\<3 months)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07148310 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Hepato Cellular Carcinoma (HCC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07148310 currently recruiting?
Yes, NCT07148310 is actively recruiting participants. Contact the research team at victoria.bocanegra@epiliquid.com for enrollment information.
Where is the NCT07148310 trial being conducted?
This trial is being conducted at Mendoza, Argentina.
Who is sponsoring the NCT07148310 clinical trial?
NCT07148310 is sponsored by Epiliquid Holding, Inc. The trial plans to enroll 200 participants.